Ginkgo Bioworks Holdings Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
DNA$12.01-2.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(165,911) | $(204,969) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 12,869 | 18,958 |
| Stock-based compensation | 40,782 | 72,986 |
| Loss on investments and equity method investments | 2,544 | 7,819 |
| Change in fair value of warrant liabilities | (940) | (1,204) |
| Change in fair value of contingent consideration liability | (926) | 5,177 |
| Non-cash lease expense | 5,637 | 8,039 |
| Non-cash in-process research and development | 16,816 | — |
| Other non-cash activity | (442) | 1,121 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable ($372 and $(26) from related parties) | (6,770) | (526) |
| Prepaid expenses and other current assets | 1,154 | 7,442 |
| Operating lease right-of-use assets | — | 2,665 |
| Other non-current assets | (707) | (2,036) |
| Accounts payable, accrued expenses and other current liabilities | 10,871 | 19,080 |
| Deferred revenue, current and non-current ($(223) and $(2,226) from related parties) | (2,912) | (17,233) |
| Operating lease liabilities, current and non-current | (4,097) | (8,521) |
| Other non-current liabilities | 2,773 | 617 |
| Net cash used in operating activities | (89,259) | (90,585) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (6,710) | (19,441) |
| Business acquisition | (5,400) | — |
| Other | — | 27 |
| Net cash used in investing activities | (12,110) | (19,414) |
| Cash flows from financing activities: | ||
| Proceeds from exercise of stock options | 70 | 12 |
| Principal payments on finance leases | (294) | (322) |
| Contingent consideration payment | (621) | — |
| Payment of equity issuance costs | — | (578) |
| Net cash used in financing activities | (845) | (888) |
| Effect of foreign exchange rates on cash and cash equivalents | (157) | (26) |
| Net decrease in cash, cash equivalents and restricted cash | (102,371) | (110,913) |
| Cash and cash equivalents, beginning of period | 944,073 | 1,315,792 |
| Restricted cash, beginning of period | 45,511 | 53,789 |
| Cash, cash equivalents and restricted cash, beginning of period | 989,584 | 1,369,581 |
| Cash and cash equivalents, end of period | 840,440 | 1,206,086 |
| Restricted cash, end of period | 46,773 | 52,582 |
| Cash, cash equivalents and restricted cash, end of period | $887,213 | $1,258,668 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.